Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018

“…In one of these cohort studies [54,58], the effect of anticoagulant versus no anticoagulant treatment was similar to that seen in the meta-analysis of controlled studies of anticoagulants in AF. Several cost-effectiveness simulations [50,[59][60][61][62][63][64][65][66][67][68], based on screening study data, have suggested that screening for AF is cost effective for both increasing quality-adjusted life years (QALYs) and reducing stroke. Additionally, opportunistic case finding (opportunistic screening) was found to be more cost effective than systematic screening in an RCT [60,61].…”

Risk Factors for Symptomatic Atrial Fibrillation-Analysis of an Outpatient Database

“…Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in practice and is the leading cause of debilitating strokes [1] , leading to significant economic burden [2] . While AF presently affects 2.7-6.1 million, it is expected to increase to 12.1 million by 2030.…”

Transforming the care of atrial fibrillation with mobile health

“…In the USA, modeling estimates have shown the population of undiagnosed AF to be approximately half a million patients with a societal health-care cost of US$3.1 billion [16]. The STROKE-STOP study provided patients in Sweden age 75 or 76 a pointof-care rhythm strip device (Zenicor Medical Systems, Stockholm, Sweden) to be used over a 2-week period and found previously undiagnosed AF in 3 % of the 7173 participants [17].…”